Editor of Patient Care Online.
Dupilumab Shows Efficacy in Eosinophilic Esophagitis Regardless of Food Elimination Diets
The impact of food elimination diets on medication previously was unknown, according to new research presented at AAAAI 2025.
Shifting Trends in Severe Asthma Biologics: Daily Dose
Your daily dose of the clinical news you may have missed.
GSK’s Depemokimab Applications Accepted for FDA Review for Asthma and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing, according to GSK.
FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose
FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature
The Loss of Pulse Detection feature will begin rolling out in the US late next month.
Nektar Therapeutics Completes Enrollment for Phase 2b Alopecia Areata Trial
The company announced completion of target enrollment in the REZOLVE-AA study of rezpegaldesleukin in people with severe-to-very-severe alopecia areata.
FDA Greenlights New Wearable Treatment for Parkinson Disease: Daily Dose
Study Finds Telehealth Use in Depression Skews Towards Higher-Wealth Patients
Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.
FDA Accepts Supplemental New Drug Application for Uzedy for Bipolar I Disorder
The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.
Transdermal Peanut Patch Shows Lasting Allergy Benefits: Daily Dose
FDA Approves Pentavalent Meningococcal Vaccine Penmenvy: Daily Dose
Home-Based Therapy Achieves 100% Success Rate in Children with High-Threshold Peanut Allergy
AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.
Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
Advancements in Actinic Keratosis Management: Expert Insights from the 2025 Winter Clinical Dermatology Conference
Neal Bhatia, MD, highlighted updates in the management of actinic keratosis, emphasizing strategies to reduce skin cancer risk and improve patient outcomes.
Key Developments in Cosmeceuticals: Highlights from the Midwinter Clinical Hawaii Derm Conference
Cheri Frey, MD, explored novel active ingredients, advancements in skin care formulations at the Midwinter Clinical Derm Conference.
Antibiotic Stewardship and Emerging Resistance: Insights from the 2025 Winter Clinical Dermatology Conference
Theodore Rosen, MD, underscored the critical need for responsible antibiotic use in dermatology to combat the accelerating crisis of drug-resistant infections.
Novel Approaches to Molluscum and HPV-Related Dermatologic Conditions
Insights into managing molluscum contagiosum, HPV-related warts, and other infections took center stage at the Midwinter Clinical Hawaii Derm Conference.
Pediatric Dermatology Treatment: An Expert Overview with Elizabeth Swanson, MD
From new biologics for AD to JAK inhibitors for children with alopecia areata, get the latest updates in pediatric dermatology, here.
4 Pearls for Managing Atopic Dermatitis
From black tea compresses to effective mind-body interventions for symptom control, Peter Lio, MD, shares 4 pearls for effective AD management.
Topical Acne Therapies: A Clinical Update
Insights include new data on combination therapies, topical antiandrogens, and innovative retinoid formulations.
Key Advances in Oral Therapies for Psoriasis Unveiled at Winter Clinical Dermatology Conference 2025
April Armstrong, MD, discussed the latest data on apremilast, deucravacitinib, and emerging TYK2 and IL-23 inhibitors at Midwinter Hawaii.
Oral Antiviral Candidate Shows Promise for RSV Treatment: Daily Dose
Ozempic Approval Expanded to Include Patients with T2D and CKD: Daily Dose
Postnatal Antibiotics for Maternal Indications May Heighten Childhood Asthma Risk
AAAAI 2025. Early postnatal antibiotic exposure in full-term infants was associated with a 30% increased risk of childhood asthma, according to a new study.
AAAAI 2025: Omalizumab Shows Favorable Outcomes Versus Oral Immunotherapy in Multi‐Food Allergy Treatment
In a randomized clinical trial, omalizumab achieved a 36% treatment success rate for multi-food allergy compared with 19% for oral immunotherapy.
Investigational Nonopioid Beats Placebo in Phase 3 Trial: Daily Dose
Investigational Cell Therapy Cuts Insulin Dependency in Late-Stage Type 2 Diabetes
CELZ-201 reduced insulin dependency and stabilized HbA1c in 1-year follow-up data from a pilot study in T2D.
New Biomarkers Identified for Early Detection of Alzheimer Disease
Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.
Heart Disease Remains Leading Cause of Death in US: Daily Dose
FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis
Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.
